Prime Medicine Inc (NASDAQ: PRME) is a biotechnology company developing one-time curative genetic therapies based on its Prime Editing technology platform. The company has no product revenue as of its 10-K filed March 3, 2026, and finances operations through equity offerings, debt financings, and collaboration agreements. Under its Beam Collaboration Agreement, Prime Medicine licenses exclusive worldwide rights to certain Prime Editing know-how and patent rights to Beam Therapeutics for use within a defined field limited to transition point mutations in human disease treatment. The company operates from facilities in Massachusetts. Allan Reine, M.D., serves as Principal Executive Officer and Principal Financial Officer as of March 3, 2026. Cash needs are met through capital markets activity and licensing arrangements, as no commercial products have reached market.

Revenue model

Prime Medicine generates no product revenue as of the 10-K filed March 3, 2026. The company funds operations through equity and convertible debt offerings, and through collaboration and licensing arrangements, including the Beam Collaboration Agreement under which it licenses Prime Editing know-how and patent rights.

Products and services

Prime Medicine's core platform is Prime Editing technology, a gene editing approach designed to make precise changes to DNA. The company describes its goal as delivering one-time curative genetic therapies across a wide spectrum of diseases. No products have received regulatory approval or been commercialized as of the filing date.

Customers and end markets

Prime Medicine's end market is human disease treatment, with product candidates targeting genetic diseases. As of the 10-K filed March 3, 2026, the company has no commercial customers. Beam Therapeutics is an identified collaboration partner under the Beam Collaboration Agreement.

Value-chain role

Prime Medicine operates as an early-stage gene editing platform developer and licensor. It licenses Prime Editing technology to partners such as Beam Therapeutics and conducts internal research and development toward clinical-stage genetic therapies.

Geographic exposure

Prime Medicine's facilities are located in Massachusetts, as disclosed in the 10-K filed March 3, 2026. The Beam Collaboration Agreement grants worldwide licensing rights.

Source: SEC 10-K, filed 2026-03-03

Industry: Biological Products, (No Diagnostic Substances) Peers: Vericel Corp CHINOOK THERAPEUTICS, INC. Avidity Biosciences, Inc. Day One Biopharmaceuticals, Inc. DYNAVAX TECHNOLOGIES CORP Iovance Biotherapeutics Inc Keros Therapeutics Inc Recursion Pharmaceuticals Inc Protagonist Therapeutics Inc